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ORIGINAL ARTICLE
Impact of Moving From a Widespread to Multisite
Pain Definition on Other Fibromyalgia Symptoms
LINDA E. DEAN,1 LESLEY ARNOLD,2 LESLIE CROFFORD,3 ROBERT BENNETT,4 DON GOLDENBERG,5
MARY-ANN FITZCHARLES,6 EDUARDO S. PAIVA,7 ROLAND STAUD,8 DAN CLAUW,9
PIERCARLO SARZI-PUTTINI,10 GARETH T. JONES,1 ABIMBOLA AYORINDE,1
ELISA FL€Uß,1 MARCUS BEASLEY,1 AND GARY J. MACFARLANE1
Objective. To investigate whether associations between pain and the additional symptoms associated with
fibromyalgia are different in persons with chronic widespread pain (CWP) compared to multisite pain (MSP), with
or without joint areas.
Methods. Six studies were used: 1958 British birth cohort, Epidemiology of Functional Disorders, Kid Low Back Pain,
Managing Unexplained Symptoms (Chronic Widespread Pain) in Primary Care: Involving Traditional and Accessible
New Approaches, Study of Health and its Management, and Women’s Health Study (WHEST; females). MSP was
defined as the presence of pain in ≥8 body sites in adults (≥10 sites in children) indicated on 4-view body manikins,
conducted first to include joints (positive joints) and second without (negative joints). The relationship between pain
and fatigue, sleep disturbance, somatic symptoms, and mood impairment was assessed using logistic regression.
Results are presented as odds ratios (ORs) with 95% confidence intervals (95% CIs).
Results. There were 34,818 participants across the study populations (adults age range 42–56 years, male 43–51% [ex-
cluding WHEST], and CWP prevalence 12–17%). Among those reporting MSP, the proportion reporting CWP ranged
between 62% and 76%. Among those reporting the symptoms associated with fibromyalgia, there was an increased
likelihood of reporting pain, the magnitude of which was similar regardless of the definition used. For example,
within WHEST, reporting moderate/severe fatigue (Chalder fatigue scale 4–11) was associated with a >5-fold increase
in likelihood of reporting pain (CWP OR 5.2 [95% CI 3.9–6.9], MSP–positive joints OR 6.5 [95% CI 5.0–8.6], and MSP–
negative joints OR 6.5 [95% CI 4.7–9.0]).
Conclusion. This large-scale study demonstrates that regardless of the pain definition used, the magnitude of associa-
tion between pain and other associated symptoms of fibromyalgia is similar. This finding supports the continued col-
lection of both when classifying fibromyalgia, but highlights the fact that pain may not require to follow the definition
outlined within the 1990 American College of Rheumatology criteria.
INTRODUCTION
The understanding and classification of pain syndromes,
such as fibromyalgia, have been evolving. Since its early
beginnings as fibrositis, interest in fibromyalgia has
steadily increased, especially with regard to strategies
used for the classification of affected individuals, which
remain controversial.
The initial American College of Rheumatology (ACR)–
endorsed 1990 classification criteria for fibromyalgia
required the presence of contralateral (left side, right
side, above waist, and below waist) and axial body pain,
in addition to pain on palpation in at least 11 (of 18)
specified anatomical points (1). Although these criteria
resulted in many clinical and epidemiologic studies,
which improved the understanding of the etiology and
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outcome of fibromyalgia, there were issues with opera-
tionalization in the clinical setting, partly due to the
inconsistency in examination for tender points (2). These
pain-centered criteria also failed to consider other com-
mon, nonpain, fibromyalgia symptoms such as fatigue.
Generally, the agreement between the ACR 1990 classifi-
cation criteria and clinical fibromyalgia diagnosis is
approximately 75% (3).
In response to these limitations, the proposed 2010
preliminary diagnostic criteria (and the 2011 modification
for research) moved fibromyalgia from a pain-focused to a
symptom-focused condition (4,5). In doing so, the pain
aspect of the criteria moved from requiring pain to be
widespread to being multisite, and the previously required
tender-point examination was removed. In addition to the
presence of chronic multisite pain (MSP; lasting ≥3
months), the proposed diagnostic criteria also required
the presence of additional symptoms associated with
fibromyalgia: fatigue, waking unrefreshed, and somatic
and cognitive symptoms. The 2010 diagnostic criteria have
provoked considerable debate and have been criticized
as being difficult to operationalize (6), and alternative
criteria have also been proposed (7). In addition, it is
also important to note that all 3 proposed criteria for
fibromyalgia (1990, preliminary 2010, and 2011 modifica-
tion) were developed in populations of rheumatic disease
patients.
In this context, the current analysis was undertaken as
part of the Analgesic, Anesthetic, and Addiction Clinical
Trial Translations, Innovations, Opportunities, and Net-
works (ACTTION) initiative to develop a new taxonomy
for pain conditions. Specifically informing the develop-
ment of a taxonomy for fibromyalgia, the aims of the cur-
rent analysis were to assess and compare the descriptive
epidemiology of pain reporting in the general population,
using widespread pain and MSP definitions (with and
without the inclusion of joints), to assess the relationship
between these pain definitions and the other associated
symptoms of fibromyalgia, and due to the predominance
of fibromyalgia in females, to determine whether there is
any sexual dimorphism in the reporting of these symp-
toms.
PATIENTS AND METHODS
Study populations. Six existing studies (5 with general
populations and 1 with a school-based sampling frame)
were used for the current post hoc analysis. In all
studies participants were asked if they had experienced,
during the previous month, aches or pains lasting for at
least 1 day. Positive responders were consequently
invited to mark the specific areas in which this pain had
occurred on 4-view blank body manikins (which were
thereafter coded with a maximum of 35 marked sites)
(Figure 1). Participants were also asked whether the pain
had lasted at least 3 months (indicating chronic pain).
Manikin coding was conducted within each study by
trained research staff. This procedure has previously
shown high interrater reliability in the classification of
widespread pain (8).
The Epidemiology of Functional Disorders (EPIFUND)
is a prospective cohort study consisting of a random
sample of subjects ages 25–65 years from 3 areas of the
UK (9). Data from the initial recruitment survey, col-
lected by means of self-complete postal questionnaire,
were used for the current analysis. Information was col-
lected on sleep problems (estimation of sleep problem
scale [10]), mood symptoms (hospital anxiety and
depression scales [11]), and the presence of somatic
symptoms (somatic symptom scale [12]).
The Kid Low Back Pain (Kid LBP) study is a prospec-
tive cohort study conducted across secondary schools in
Cheshire and North Derbyshire, UK (13). School children
ages 11–14 years were eligible for the study. Data from
the initial self-complete questionnaire were used for the
current analysis.
The Managing Unexplained Symptoms (Chronic Wide-
spread Pain) in Primary Care: Involving Traditional and
Accessible New Approaches (MUSICIAN) study is a 292
factorial randomized controlled trial, undertaken to
investigate the management of chronic widespread pain
(CWP) (14). General practitioner practices across Aber-
deen City and North Cheshire County of the UK were
used as a sampling frame, from which randomly selected
individuals ages ≤25 years were sent a self-complete
screening questionnaire by mail. Those data were used
in the current analysis.
The Study of Health and its Management (SHAMA) is
a cross-sectional study of individuals residing in the
Grampian region of the UK, ages ≤25 years (15) who self-
completed a questionnaire sent by mail. The question-
naire included a measurement of quality of life (Short
Form 36 health survey [SF-36]) (16).
The National Child Development (1958 British birth
cohort) study included all children born in Great Britain
during a single week in March 1958. Subjects have been
followed over the course of their lifetime (17). In 2003
(when the cohort was 45 years old), participants self-
completed a questionnaire that included a measure of
psychological distress (general health questionnaire) (18).
Significance & Innovations
• We have developed a description of multisite
pain that gives a similar prevalence to chronic
widespread pain, defined as the presence of ≥8
pain sites.
• The magnitude of association between pain and
the symptoms associated with fibromyalgia is
similar, regardless of whether joint areas were
included in the definition of multisite pain or
not.
• The continued collection of information on both
pain and associated symptoms when classifying
fibromyalgia remains important, but the defini-
tion of pain may not necessarily require follow-
ing the definition outlined in the 1990 American
College of Rheumatology criteria for fibromyalgia.
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The Women’s Health Study (WHEST) is a cross-sec-
tional study of females, ages ≤25 years, resident in the
Grampian region of the UK, who were sent a self-complete
questionnaire by post. This questionnaire included mea-
sures of fatigue (Chalder fatigue scale [19]), sleep distur-
bance (estimation of sleep problem scale [10]), somatic
symptom reporting (somatic symptom scale [12]), and
depression (patient health questionnaire–9 [20]).
Consent was obtained from potential participants
within each original study as per their individual gover-
nance arrangements. All data used within the current
study were fully anonymized.
Classification of pain. Participants were classified as
having widespread pain (contralateral pain and pain in
the axial skeleton), CWP (widespread pain lasting ≥3
months), regional pain (pain that was not widespread), or
no pain (1). The cumulative distribution of the number of
painful body sites was examined within each of the 6
study populations and was used to determine definitions
of MSP that produced the closest prevalence to CWP
(according to the ACR 1990 definition). As an example, if
X% of the study population reported CWP (ACR 1990), we
chose the number of sites whose cumulative prevalence
was closest to 100-X% as the definition of MSP. This
process was conducted twice, once to include all body
locations, hereafter defined as MSP–positive joints, and
secondly with the exclusion of all 10 joint areas, hereafter
defined as MSP–negative joints.
Statistical analysis. The characteristics of each of the
populations, and the subgroups fulfilling the CWP, MSP–
positive joints, and MSP–negative joints definitions, were
examined using simple descriptive statistics, reported as
proportions for categorical variables and population mean
 SD for continuous factors. The relationship between the
additional symptoms associated with fibromyalgia, and
the reporting of each of these pain definitions, were
assessed using multiple binary logistic regression models.
Fatigue was assessed using the Chalder fatigue scale,
categorized by standard cutoffs into none (score 0), mild
(scores 1–3) and moderate/severe (scores 4–11) (19), or
the SF-36 vitality score. Due to the skewed distribution of
the data, a pragmatic approach was chosen to categorize the
SF-36 vitality into tertiles, high (scores 81–100), mid (scores
58–80), and poor (scores 0–57) (16). All analyses were
thereafter conducted comparing the poorest tertile to the
middle and highest combined, to maximize patient
number while also retaining a clinically meaningful
group. Sleep problems were assessed using the estimation
of sleep problem scale, categorized by standard cutoffs as
no sleep problems (scores 0–11) or sleep problems (scores
12–20) (10), and the presence of any somatic symptoms
was assessed by the somatic symptom scale (12). Lastly,
emotional/mental health was assessed by 4 different
instruments. The general health questionnaire was
subdivided into tertiles of high (score 0), mid (scores 1–2),
and poor (scores 3–12) (18). The patient health questionnaire
was subdivided into mild, moderate, moderately severe,
and severe according to standard instrument cutoffs (21).
The SF-36 mental health score was divided into tertiles
due to skewed distribution (poor [score 0–79], mid [scores
80–86], and high [scores 87–100]) (16), and analysis was
conducted on the poorest versus the mid and high groups.
Lastly the hospital anxiety and depression scales were
grouped into scores of no, borderline, and clinical
anxiety/depression according to standard instrument
cutoffs (11).
Additionally, to assess potential sexual dimorphism, of
those reporting MSP–positive joints, differences in the
reporting of the additional symptoms associated with
fibromyalgia were assessed, stratified by sex. For all
Figure 1. Four-view body manikins with scoring.
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logistic regression models, results are presented as odds
ratios (ORs) and 95% confidence intervals (95% CIs). All
statistical analysis was undertaken using STATA soft-
ware, version 13.
RESULTS
Characteristics of study populations. The total number
of participants was 34,818, and the number from each
study varied from 1,440 (Kid LBP) to 14,680 (MUSICIAN).
Excluding WHEST, which contained only females, the
proportion of male participants ranged between 43% and
51% (Table 1). The mean age range within the adult
cohorts was narrow, 42–56 years, while children in the Kid
LBP study had a mean age of 12 years. The prevalence of
CWP within the adult studies varied between 12% and
17% and was lower within the only child population (7%)
(Table 1).
MSP definition. Although the prevalence of CWP
differed between the adult study populations, the number
of corresponding sites defining both MSP–positive joints
and MSP–negative joints definitions was consistent across
all studies, namely ≥8 sites (Table 2). The corresponding
MSP (positive and negative joints) definitions were
different only within the child population, which used at
least 10 sites.
There was substantial overlap between CWP and MSP
groups (Table 2). Within the adult populations, of per-
sons satisfying the definition of MSP–positive joints,
between 62% and 72% also fulfilled the CWP definition.
Among those meeting the MSP–negative joints definition,
between 68% and 79% also met the definition of CWP.
Among the child population, those also fulfilling the
CWP definition were substantially lower (MSP positive
39% and MSP negative 42%). There was consistency in
the mean age and sex proportions across the adult
population groups (Table 3). For example, within the
EPIFUND study, the mean  SD age in both CWP and
MSP–positive joints groups was 48  11 years and in the
MSP–negative joints groups was 47  11 years. The pro-
portion of males in the same study was 36%, 35%, and
30%, for CWP, MSP–positive joints, and MSP–negative
joints groups, respectively.
Relationship between pain and the additional symptoms
associated with fibromyalgia. The populations meeting
the CWP, MSP–positive joints, and MSP–negative joints
criteria were characterized by their reporting of fatigue, sleep
problems, somatic symptoms and mental/emotional health.
Fatigue. Fatigue was assessed within 2 studies
(SHAMA and WHEST). Those who reported fatigue were
more likely to report pain, regardless of the pain definition
used (Table 4). The magnitude of this association was
greater with MSP definitions. For example, within the
WHEST study, compared to no fatigue, reporting
moderate/severe fatigue was associated with a 5-fold
increase in the odds of CWP (OR 5.2 [95% CI 3.9–6.9]) and
a 6.5-fold increase in the odds of MSP (MSP–positive
joints OR 6.5 [95% CI 5.0–8.6]; MSP–negative joints OR
6.5 [95% CI 4.7–9.0]) (Table 4).
Table 1. Characteristics of those in the included studies who answered pain question*
SHAMA WHEST EPIFUND MUSICIAN Kid LBP 1958 BBC
No. 1,579 2,303 6,244 14,680 1,440 8,572
Male, % 45 0 43 43 46 51
Age, mean  SD years 55  15 53  15 46  11 56  16 12  0.9 42 (–)
Type of pain, no. (%)
None 782 (50) 1,028 (45) 2,343 (38) 5,424 (37) 390 (27) 4,019 (47)
Regional 570 (36) 884 (38) 2,709 (43) 6,601 (45) 863 (60) 3,318 (39)
Widespread 30 (2) 54 (2) 129 (2) 239 (2) 109 (8) 179 (2)
Chronic widespread 197 (12) 337 (15) 1,063 (17) 2,416 (16) 78 (5) 1,056 (12)
* SHAMA = Study of Health and its Management; WHEST = Women’s Health Study; EPIFUND = Epidemiology of Functional
Disorders; MUSICIAN = Managing Unexplained Symptoms (Chronic Widespread Pain) in Primary Care: Involving Traditional and
Accessible New Approaches; Kid LBP = Kid Low Back Pain; BBC = British birth cohort.
Table 2. New multisite definitions and comparisons with CWP definition with positive and negative joints*
MSP definition
SHAMA WHEST EPIFUND MUSICIAN Kid LBP 1958 BBC
Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg. Pos. Neg.
No. of sites for definition ≥8 ≥8 ≥8 ≥8 ≥8 ≥8 ≥8 ≥8 ≥10 ≥10 ≥8 ≥8
No. of those fulfilling MSP 219 136 397 235 1,061 568 2,715 1,623 84 26 1,110 633
Percent who also had CWP 62 68 66 75 72 75 68 79 39 42 66 74
* Chronic widespread pain (CWP) defined according to the American College of Rheumatology 1990 criteria. SHAMA = Study of Health
and its Management; WHEST = Women’s Health Study; EPIFUND = Epidemiology of Functional Disorders; MUSICIAN = Managing Unex-
plained Symptoms (Chronic Widespread Pain) in Primary Care: Involving Traditional and Accessible New Approaches; Kid LBP = Kid
Low Back Pain; BBC = British birth cohort; MSP = multisite pain; Pos. = positive; Neg. = negative.
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Sleep problems. Sleep problems were assessed within
2 studies (WHEST and EPIFUND). Those who reported
sleep problems had a 4-fold increased odds of reporting
pain (Table 4), and this result was consistent across pain
definitions. For example, within the EPIFUND study,
CWP was OR 4.1 (95% CI 3.6–4.8), MSP–positive joints
OR 4.1 (95% CI 3.6–4.8), and MSP–negative joints OR
4.2 (95% CI 3.5–5.0) (Table 4).
Somatic symptoms. Somatic symptoms were assessed
within 2 studies (WHEST and EPIFUND). The reporting
of any somatic symptom was associated with an increased
odds of reporting pain. The magnitude of this association
was similar across all pain definitions for each individual
symptom. For example, within the EPIFUND study, reporting
breathing difficulties was associated with approximately a
2.5-fold increase in the odds of reporting pain: CWP OR 2.5
(95% CI 2.1–2.8), MSP–positive joints OR 2.6 (95% CI 2.3–
3.0), and MSP–negative joints OR 2.7 (95% CI 2.3–3.3)
(Table 4). The only notable difference in pain reporting was
demonstrated within the somatic symptom of digit pain, in
which the odds of pain reporting were larger for MSP–
positive joints compared to the other pain groups: CWP OR
4.2 (95% CI 3.7–4.9), MSP–positive joints OR 5.2 (95% CI
4.5–5.9), and MSP–negative joints OR 4.6 (95% CI 3.9–5.5)
(Table 4).
Mental and emotional health. Mental/emotional health
was assessed within 4 studies (1958 British birth cohort,
WHEST, SHAMA, and EPIFUND). Generally, reporting
impaired mental health was associated with an increased
odds of reporting pain (Table 4). The magnitude of this
association increased as the severity of mental health
problems worsened but was consistent across pain
definitions. As an example, within the EPIFUND study and
using the HADS scale, reporting borderline depression was
associated with at least a 2.5-fold increase in the odds of
pain (CWP OR 2.5 [95% CI 2.1–3.1], MSP–positive joints
OR 2.5 [95% CI 2.0–2.99], and MSP–negative joints OR 2.9
[95% CI 2.3–3.7]), while reporting clinical depression was
associated with a <4-fold increase in the odds of pain
(CWP OR 4.5 [95% CI 3.6–5.5], MSP–positive joints OR 4.2
[95% CI 3.4–5.2], and MSP–negative joints OR 4.7 [95% CI
3.7–6.0]) (Table 4).
Relationship between pain and the additional symptoms
associated with fibromyalgia, stratified by sex. With the
aim of assessing potential sexual dimorphism, stratification
was used to assess sex differences in the association
between pain reporting (MSP–positive joints) and other
additional symptoms associated with fibromyalgia. Report-
ing fatigue was associated with an increased odds of
reporting pain regardless of sex (Table 5). Among females,
compared to those reporting moderate/high vitality (SF-36
vitality score 58–100), those reporting poor vitality (score
0–57) had a 5-fold increase in the odds of also reporting
MSP–positive joints (OR 5.1 [95% CI 3.3–7.7]). Within
males, the odds of pain reporting in the presence of poor
vitality was OR 4.4 (95% CI 2.7–7.1). Those who reported
sleep problems demonstrated an increased odds of
reporting MSP–positive joints, and the magnitude of this
association was similar across both males and females:
male OR 4.4 (95% CI 3.5–5.6); female OR 3.8 (95% CI
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3.2–4.6) (Table 5). Additionally, those reporting somatic
symptoms were more likely to report MSP–positive joints
(Table 5), and the magnitude of this result was similar
across sex. For example, reporting breathing difficulties
was associated with approximately a 2.5-fold increase in
the odds of pain in both males (OR 2.4 [95% CI 1.9–3.1])
and females (OR 2.6 [95% CI 2.2–3.1]). Lastly, those who
reported impaired mental health were more likely to report
Table 4. Relationship between MSP/CWP and symptoms associated with fibromyalgia*
Measure (study population)
CWP MSP–positive joints MSP–negative joints
No. OR (95% CI) No. OR (95% CI) No. OR (95% CI)
Fatigue
SF-36 vitality vs. medium/high tertile: score
58–100 (SHAMA)
Poor: score 0–57 1,579 5.3 (3.8–7.5)† 1,579 4.9 (3.5–6.7)† 1,579 5.1 (3.4–7.6)†
Chalder fatigue scale vs. absent (WHEST)
Mild: score 1–3 2,178 2.9 (2.1–3.9)† 2,178 3.0 (2.2–4.0)† 2,178 3.0 (2.1–4.3)†
Moderate/severe: score 4–11 2,178 5.2 (3.9–6.9)† 2,178 6.5 (5.0–8.6)† 2,178 6.5 (4.7–9.0)†
Sleep problems
Estimation of sleep problems vs. no (WHEST)
Yes 2,258 3.6 (2.9–4.7)† 2,258 3.8 (3.0–4.7)† 2,258 4.3 (3.3–5.7)†
Estimation of sleep problems vs. no (EPIFUND)
Yes 6,039 4.1 (3.6–4.8)† 6,027 4.1 (3.6–4.8)† 6,039 4.2 (3.5–5.0)
Somatic symptoms present
Somatic symptom scale, yes vs. no (WHEST)
Breathing difficulties 2,291 2.7 (2.1–3.4)† 2,291 3.1 (2.5–3.9)† 1,195 2.0 (1.5–2.6)†
Menstrual cramps 2,276 2.4 (1.9–3.1)† 2,276 2.3 (1.8–2.8)† 1,187 2.1 (1.6–2.8)†
Lost voice 2,290 1.3 (1.0–1.8) 2,290 1.6 (1.2–2.1)† 1,195 1.1 (0.8–1.7)
Difficulty swallowing 2,298 2.9 (2.2–3.7)† 2,298 3.0 (2.3–3.8)† 1,200 1.9 (1.4–2.6)†
Memory loss 2,293 2.9 (2.2–4.0)† 2,293 3.4 (2.5–4.5)† 1,194 2.6 (1.8–3.6)†
Frequently vomit 2,294 2.4 (1.6–3.6)† 2,294 2.5 (1.7–3.7)† 1,197 1.9 (1.2–3.0)‡
Digit pain 2,289 4.8 (3.7–6.2)† 2,289 5.7 (4.4–7.2)† 1,192 2.3 (1.7–3.1)†
Somatic symptom scale, yes vs. no (EPIFUND)
Breathing difficulties 6,196 2.5 (2.1–2.8)† 6,210 2.6 (2.3–3.0)† 6,210 2.7 (2.3–3.3)†
Menstrual cramps 3,426 1.7 (1.4–2.0)† 3,432 1.7 (1.4–2.0)† 3,432 1.8 (1.5–2.3)†
Lost voice 6,214 1.5 (1.3–1.8)† 6,228 1.4 (1.2–1.7)† 6,228 1.5 (1.2–1.8)‡
Difficulty swallowing 5,326 2.7 (2.3–3.2)† 5,338 2.7 (2.3–3.2)† 5,338 2.6 (2.1–3.2)†
Memory loss 6,208 2.5 (2.1–3.0)† 6,221 2.4 (2.0–2.9)† 6,221 2.4 (1.9–3.0)†
Frequently vomit 6,185 2.8 (2.2–3.7)† 6,198 2.8 (2.1–3.7)† 6,198 3.4 (2.5–4.7)†
Digit pain 6,187 4.2 (3.7–4.9)† 6,201 5.2 (4.5–5.9)† 6,201 4.6 (3.9–5.5)†
Emotional/mental health
General health questionnaire vs. top tertile:
score 0 (1958 British birth cohort)
Mid: score 1–2 8,283 1.5 (1.3–1.8)† 8,283 1.3 (1.1–1.5)‡ 8,283 1.3 (1.1–1.7)†
Poor: score 3–12 8,283 2.3 (1.9–2.7)† 8,283 2.2 (1.9–2.6)† 8,283 2.5 (2.1–3.1)†
Patient health questionnaire–9 vs. no depression
(WHEST)
Mild depression 2,215 3.4 (2.6–4.5)† 2,215 3.3 (2.5–4.5)† 1,145 2.1 (1.5–3.1)†
Moderate depression 2,215 7.1 (5.0–10.1)† 2,215 5.7 (3.9–8.2)† 1,145 4.1 (2.7–6.4)†
Moderately severe depression 2,215 10.5 (6.4–17.3)† 2,215 10.5 (6.4–17.4)† 1,145 7.9 (4.3–14.3)†
Severe depression 2,215 11.2 (6.0–21.1)† 2,215 9.1 (4.8–17.3)† 1,145 7.9 (3.6–17.2)†
SF-36 mental health vs. medium/high tertile:
score 80–100 (SHAMA)
Poor (score 0–79) 1,578 2.9 (2.1–3.9)† 1,578 3.3 (2.4–4.5)† 1,578 3.2 (2.2–4.7)†
Hospital anxiety and depression scale vs. none:
score 0–7 (EPIFUND)
Anxiety borderline: score 8–10 6,161 1.9 (1.6–2.3)† 6,148 1.8 (1.5–2.1)† 6,161 2.1 (1.7–2.7)†
Anxiety present: score 11–21 6,161 3.2 (2.7–3.7)† 6,148 3.2 (2.7–3.8)† 6,161 3.3 (2.7–3.7)†
Depression borderline: score 8–10 6,169 2.5 (2.1–3.1)† 6,155 2.5 (2.0–3.0)† 6,169 2.9 (2.3–3.7)†
Depression present: score 11–21 6,169 4.5 (3.6–5.5)† 6,155 4.2 (3.4–5.2)† 6,161 4.7 (3.7–6.0)†
* Values are the number of subjects included in each model. MSP = multisite pain; CWP = widespread pain; OR = odds ratio; 95% CI = 95% confi-
dence interval; SF-36 = Short Form 36 health survey; SHAMA = Study of Health and its Management; WHEST = Women’s Health Study; EPIFUND =
Epidemiology of Functional Disorders.
† P < 0.001.
‡ P < 0.05.
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MSP–positive joints regardless of sex (Table 5). For
example, reporting borderline depression (compared to no
depression) was associated with over a doubling in the odds
of pain (male OR 2.9 [95% CI 2.1–4.1]; female OR 2.3 [95%
CI 1.8–2.9]) and reporting clinical depression was associated
with over a quadrupling in the odds of pain (male OR 5.0
[95% CI 3.6–7.0]; female OR 4.2 [95% CI 3.2–5.5]).
In addition to the raw comparison of the relationship
between pain and the additional associated symptoms of
fibromyalgia by sex, potential differences were further
assessed using interaction terms. These additional mod-
els (data not shown) confirmed that there were no statis-
tically significant interactions between sex and fatigue,
sleep problems, somatic symptoms, or mental/emotional
health (P > 0.05 for all).
DISCUSSION
We have demonstrated that there is little difference, and
the magnitude of association was similar between fatigue,
sleep disturbance, the reporting of somatic symptoms, or
cognitive problems and CWP or MSP (with or without
consideration of joint pain). Additionally, there is no
indication of systematic differences in the magnitude of
these associations by sex.
There are a number of methodologic considerations in
interpreting the current findings. First, one of the primary
aims of the study was to assess the relationship between
alternative pain area definitions (CWP/MSP) and the addi-
tional associated symptoms of fibromyalgia. The MSP defi-
nition was formulated in such a way as to identify a
population that gave a similar prevalence to that of CWP.
Due to this coordination, one may expect that both groups
would include many of the same individuals, and there-
fore the study would have only modest power to detect
potential differences. The overlap observed was between
60% and 76%, leaving a substantial number of unique
individuals within each group. Additionally, the character-
istics of those within the groups differed, pain chronicity
being the most apparent. By definition, 100% of the CWP
group experienced chronic pain (pain ≥3 months dura-
tion); however, within the MSP groups, this dropped to as
low as 77% (adult population). The similarities shown
between groups are therefore not solely due to the overlap
of patients, although this overlap will have contributed.
The relationship between pain and the other associated
symptoms of fibromyalgia was assessed through bivariate
analysis, using studies that contained both a measure of
pain (which allowed the classification of CWP and MSP)
and at least 1 of the associated symptoms that fibromyalgia
Table 5. Relationship between MSP (positive joints) and symptoms associated with fibromyalgia, stratified by sex*
Measure (study population)
Males Females
No. OR (95% CI) No. OR (95% CI)
Fatigue
SF-36 vitality vs. medium/high tertile: score 58–100 (SHAMA)
Poor: score 0–57 705 4.4 (2.7–7.1)† 874 5.1 (3.3–7.7)†
Sleep problems
Estimation of sleep problems vs. no (EPIFUND)
Yes 2,631 4.4 (3.5–5.6)† 3,408 3.8 (3.2–4.6)†
Somatic symptoms
Somatic symptom scale, yes vs. no (EPIFUND)
Breathing difficulties 2,706 2.4 (1.9–3.1)† 3,504 2.6 (2.2–3.1)†
Menstrual cramps – 3,400 1.7 (1.4–2.0)†
Lost voice 2,709 1.2 (0.8–1.7) 3,519 1.3 (1.1–1.6)‡
Difficulty swallowing 2,360 2.9 (2.2–3.9)† 2,975 2.5 (2.0–3.1)†
Memory loss 2,704 2.7 (2.0–3.6)† 3,517 2.3 (1.8–2.9)†
Frequently vomit 2,686 2.8 (1.7–4.6)† 3,512 2.7 (1.9–3.7)†
Digit pain 2,699 4.8 (3.9–6.1)† 3,502 5.2 (4.4–6.3)†
Emotional/mental health
General health questionnaire vs. top tertile: score 0 (1958 British birth cohort)
Mid: score 1–2 4,046 1.1 (0.9–1.4) 4,237 1.5 (1.2–1.9)†
Poor: score 3–12 4,046 1.9 (1.5–2.4)† 4,237 2.5 (2.0–3.1)†
SF-36 mental health vs. medium/high tertile: score 80–100 (SHAMA)
Poor: score 0–79 705 3.3 (2.0–5.3)† 873 3.2 (2.2–4.7)†
Hospital anxiety and depression scale vs. none: score 0–7 (EPIFUND)
Anxiety borderline: score 8–10 2,685 2.3 (1.7–3.0)† 3,476 1.6 (1.3–2.0)†
Anxiety present: score 11–21 2,685 3.8 (2.9–5.0)† 3,476 2.7 (2.2–3.3)†
Depression borderline: score 8–10 2,681 2.9 (2.1–4.1)† 3,488 2.3 (1.8–2.9)†
Depression present: score 11–21 2,681 5.0 (3.6–7.0)† 3,488 4.2 (3.2–5.5)†
* Numbers are the model number. MSP = multisite pain; OR = odds ratio; 95% CI = 95% confidence interval; SF-36 = Short Form 36 health survey;
SHAMA = Study of Health and its Management; EPIFUND = Epidemiology of Functional Disorders.
† P < 0.001.
‡ P < 0.05.
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features. Unfortunately, no single study contained all pre-
dictors; therefore, a fully adjusted model could not be cre-
ated. Although the aim here was to deduce how these
features individually predicted pain, future studies assess-
ing whether these relationships remain when controlling
for the other symptoms would be valuable.
Additionally, although the magnitude of association
between these symptoms and pain was broadly similar
across pain definition, there were differences noted across
the study and measure used. Although there was little
overlap in the instruments across studies, both WHEST
and EPIFUND collected identical sleep disturbance and
somatic symptom measures. The results from these stud-
ies exhibited small differences in the magnitude of associ-
ation with pain, differences that may largely be due to the
study populations themselves. While EPIFUND is a gen-
eral population survey, WHEST only recruited females,
and as females are generally more likely to report symp-
toms such as insomnia and sleep disturbance (22), these
differences are perhaps not surprising. Conversely, multi-
ple instruments were used to measure both fatigue and
emotional/mental health. Although differences in the
magnitude of association with pain can partly be attributed
to the fact that the instruments used, although broadly
measuring similar concepts, are not identical and may be
expected to be capturing slightly different aspects.
Although there were differences in OR across measures,
all multiple-level outcomes demonstrated similar dose-
relationship trends, e.g., the worse the mental/emotional
category the greater the likelihood of reporting pain.
Within the current study, 4-view body manikins were
used to assess pain areas rather than those areas presented
in list form, as they are within the published fibromyalgia
criteria (1,4,5). As the 2011 modification, for use within
epidemiologic and clinical studies, is a relatively recent
development, none of the population studies used in the
current analysis included this modification. Pain areas
were assessed through the pain manikins across all 6
studies. The number of pain sites needed (≥8) to define
MSP within the adult studies was identical and is consis-
tent with those proposed within other studies (23).
This large-scale post hoc study, encompassing over 34,000
individuals across multiple studies, is the first to assess the
association between different pain area definitions and the
relationship with the other symptoms associated with
fibromyalgia, and demonstrated similar magnitudes of asso-
ciation, regardless of the definition used. In the absence of
gold standard criteria for fibromyalgia, we have shown that
there may be multiple ways in which the core feature of this
syndrome, namely pain, could be defined, a concept that
has been demonstrated in other conditions, such as within
the classification of shoulder pain (24). Although CWP is the
underpinning concept of the ACR 1990 classification of
fibromyalgia, its prevalence differs considerably based on
the specific definition used (25). In line with previous stud-
ies that sought to compare associations of widespread pain
and MSP with known risk factors, the current study sup-
ports classification of pain simply by number of sites
(26,27).
The original ACR 1990 classification criteria included
a definition of pain distribution that is widespread and
included joint areas (1), but the more recent 2010/2011
modifications have gone on to classify MSP without con-
sidering many of the original joint areas (4,5). Within the
current study we aimed to determine whether the rein-
clusion of joints within an MSP definition would result
in differences in the relationship with the additional fea-
tures of fibromyalgia. The results have shown, in fact,
that there is little difference in the relationship between
pain and the other features, regardless as to whether joint
areas were included or not. Excluding these areas from
classification criteria may omit a large proportion of indi-
viduals who exhibit pain in multiple sites but due to the
specific location of these sites do not meet the current
widespread definition (4,5). Future classification criteria
for fibromyalgia may consider the reinclusion of joint
areas within the definition of pain.
The current study also aimed to determine, among
those fulfilling the new definition of MSP, whether there
were sex differences in the reporting of the other features
of fibromyalgia. Although fibromyalgia is more common
in females (particularly when 1990 or clinical diagnoses
are used [6]), the current study did not provide evidence
of differences in the relationship between pain and these
features. This finding is consistent with previous studies
which have shown that there is little difference by sex in
the reporting of symptoms such as anxiety/depression
(28–30) and somatic symptoms (29) among those reporting
pain.
Lastly, in addition to including several independent
adult populations, the current study also included a
study in schoolchildren (Kid LBP study). Within the
juvenile population, the prevalence of CWP was lower
than within adults, but regional pain was more common.
This finding may be explained, in part, by the develop-
mental stage of the study participants and indicates that
standard adult definitions of pain may not be suitable for
child populations. Furthermore, the classification of
widespread pain and MSP may need to be made differ-
ently in this group. This conclusion is supported by pre-
vious studies that indicated differences in the reporting
of fibromyalgia symptoms in young adults (31). Specif-
ically, the additional features of fibromyalgia (notably
sleep quality and depressive symptoms) demonstrated
stronger association with symptom severity than for
widespread pain.
To our knowledge, this is the largest study (using
information on over 34,000 individuals across multiple
studies) to have assessed the association between pain
areas and the other associated symptoms of fibromyalgia
in the context of alternative pain definitions. We have
demonstrated similar magnitudes of association with
chronic widespread pain and MSP (whether or not joint
areas are included). Although the results presented here
should be further validated within other populations out-
side the UK, researchers and clinicians alike should be
advised that the continued collection of information on
the additional associated symptoms of fibromyalgia, in
conjunction with pain, remain important when classify-
ing fibromyalgia, but that this pain definition may not
necessarily require to follow the distribution outlined by
the 1990 ACR criteria for fibromyalgia.
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